Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma.

Authors: Abazis-Stamboulieh, D  Oikonomou, P  Papadoulis, N  Panayiotidis, P  Vrakidou, E  Tsezou, A 
Citation: Abazis-Stamboulieh D, etal., Leuk Lymphoma. 2007 Nov;48(11):2196-203.
Pubmed: (View Article at PubMed) PMID:17926179
DOI: Full-text: DOI:10.1080/10428190701615892

Interleukin-1 (IL-1) is a cytokine involved in the maturation and proliferation of B cells and plays a significant role in the development of lytic bone lesions, a major clinical feature of multiple myeloma (MM) patients. Genes that regulate products involved in the immune system are highly polymorphic and contribute to inter-individual differences that can influence the genetic predisposition and progression of particular diseases and cancers. In this study, we investigated the correlation between the single nucleotide polymorphisms IL1A -889, IL1B -511, IL1B +3954, IL1RN Mspa1 +11100 and susceptibility to MM in 74 patients and 160 controls. We found that individuals possessing IL1A -889 CT polymorphism had a higher risk in developing MM. Moreover, genotypes IL1B -511 CC, IL1B +3954 CC, IL-1RN Mspa1 +11100 CC and the combination of IL1B +3954 CC with IL1B -511 CC or IL-1RN Mspa1 +11100 CC exerted a protective effect in individuals possessing them.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11051973
Created: 2016-04-12
Species: All species
Last Modified: 2016-04-12
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.